Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Novel Compound GPX-150 Shows Promise in Soft Tissue Sarcoma

February 23rd 2017

Brian Van Tine, MD, PhD, discusses the potential of the investigational compound 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and nonresectable soft tissue sarcoma.

Dr. Albertsmeier on Radiation Therapy for Soft Tissue Sarcoma

February 21st 2017

Marcus Albertsmeier, MD, surgeon at Ludwig Maximilian University of Munich, discusses the effect of radiation therapy on local recurrence and overall survival for patients with soft tissue sarcoma.

Dr. Wilky on Pembrolizumab Plus Axitinib in Sarcoma

February 18th 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses a phase II trial exploring concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Dr. Gordon on Immunotherapy Treatment for Osteosarcoma

February 17th 2017

Nancy B. Gordon, MD, assistant professor, department of pediatrics, The University of Texas MD Anderson Center, discusses immunotherapy treatments for osteosarcoma.

EBRT Lowers Local Recurrence Risk in Soft Tissue Sarcoma

February 13th 2017

Markus Albertsmeier, MD, discusses the results of the meta-analysis and the implications going forward for the treatment of patients with soft tissue sarcoma.

Dr. Blay on the Heterogeneity of Soft Tissue Sarcoma

February 7th 2017

Jean-Yves Blay, MD, PhD, professor of Medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the heterogeneity of soft tissue sarcoma.

PD-1 Blockade Potential Comes to Light in Sarcoma Subtypes

February 6th 2017

An immunohistochemistry analysis of a large patient population demonstrated that several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings presented at the 2017 European Cancer Congress in Amsterdam.

Dr. Grignani on the Role of Trabectedin in Sarcoma

February 4th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses some of the data seen thus far with trabectedin as a treatment for patients with sarcoma.

Dr. Pollack on the Potential Impact of Radiomics on the Sarcoma Treatment Landscape

February 3rd 2017

Seth M. Pollack, MD, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the potential impact that radiomics could have on the treatment landscape of sarcoma.

Dr. Catton on Omitting Radiation Therapy in Sarcoma

January 25th 2017

Charles Catton, MD, professor, Department of Radiation Oncology, University of Toronto, discusses the notion of omitting radiation therapy in the treatment of patients with extremity sarcoma.

Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue Sarcoma

January 21st 2017

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

Dr. Kasper on Imatinib in Resistant Progressive Desmoid Tumors

January 20th 2017

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses results of a phase II study exploring the efficacy of imatinib (Gleevac) in patients with racist progressive demoed tumors.

Dr. Burgess on Pembrolizumab in Sarcoma

January 17th 2017

In the phase II SARC028 trial, single-agent pembrolizumab (Keytruda) demonstrated antitumor activity in patients with advanced soft tissue and bone sarcomas.

Efforts Continue to Expand Immunotherapy Impact in Sarcoma

January 12th 2017

Researchers are hoping the immunotherapy revolution occurring across several cancer types will extend to the field of sarcoma.

Expert Discusses Factors Associated With Local Control in Ewing Sarcoma

January 9th 2017

According to Dimosthenis Andreou, MD, patients with pelvic Ewing sarcoma have poorer local control and poorer overall survival.

Preclinical Activity With Olaratumab in Sarcoma

January 6th 2017

Caitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses preclinical activity with olaratumab (Lynparza) in pediatric sarcoma models.

Expert Anticipates Immunotherapy to Open Door to Novel Treatments in Osteosarcoma

January 3rd 2017

According to Nancy Gordon, MD, immunotherapy stands to play a critical role in the treatment of patients with osteosarcoma and lung metastases.

Immunotherapy Agents Emerging as Key Players in Sarcoma

December 16th 2016

Excitement continues to surround the potential role of immunotherapy agents in the treatment of patients with sarcoma, according to Breelyn Wilky, MD.

Expert Praises Predictive Role of Radiomics in Sarcoma

December 15th 2016

Several challenges remain in the treatment landscape of soft tissue sarcoma, a disease whose diagnosis can range from one that is quite indolent for patients, to a more life-threatening, metastatic, aggressive cancer.

TRC105/Pazopanib Combo Shows Promising Antitumor Activity in Advanced Angiosarcoma

December 15th 2016

The combination of TRC105, an endoglin antibody, and pazopanib demonstrated promising antitumor activity in patients with advanced angiosarcoma